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PURPOSE. The purpose of this study was to study the effects of panretinal photocoagulation
(PRP) and intravitreal aflibercept on retinal vessel oxygen saturations, area of retinal
nonperfusion, and area of neovascularization in proliferative diabetic retinopathy.
METHODS. This is a prospective randomized single center study. Forty patients with
proliferative diabetic retinopathy were randomized to PRP or intravitreal aflibercept
treatment for 52 weeks. Retinal oximetry and ultra-widefield angiography were performed
at baseline and week 52. Ultra-widefield color fundus imaging was performed at baseline,
week 12, and week 52. The outcomes were retinal arterio-venous oximetry differences (AVD),
area of retinal nonperfusion, and area of neovascularization in disc areas (DA).
RESULTS. The AVD in the PRP group increased from 36.7% at baseline to 39.7%, whereas it
decreased from 33.4% to 32.5% in the aflibercept group. The difference in AVD between
groups at week 52 was 4.0% (95% confidence interval, 0.08, 8.8; P ¼ 0.10). The baseline
mean area of retinal nonperfusion of 125.1 DA and 131.2 DA in the PRP and aflibercept
groups increased to 156.1 DA and 158.4 DA, respectively, at week 52 (P ¼ 0.46). The median
baseline area of neovascularization decreased from 0.98 DA to 0.68 DA in the PRP group and
from 0.70 DA to 0 DA in the aflibercept group at week 12 (P ¼ 0.019). At week 52, this
measured 0.24 DA in the PRP group and 0 DA in the aflibercept group (P ¼ 0.45).
CONCLUSIONS. Intravitreal aflibercept achieved an earlier and complete regression of
neovascularization in proliferative diabetic retinopathy compared with PRP. There were no
significant differences in global change in intravascular oxygen saturation or areas of retinal
nonperfusion between the two groups by 52 weeks.
Keywords: aflibercept, diabetic retinopathy, oximetry, panretinal photocoagulation, retinal
nonperfusion
Proliferative diabetic retinopathy (PDR) is characterized bythe development of new vessels on the retina and/or optic
disc. A key predictor of the development of these new vessels is
the total area of retinal capillary nonperfusion. Ablation of areas
of nonperfusion by panretinal photocoagulation (PRP) causes
regression of new vessels identifying a relationship between
nonperfusion and neovascularization.1–4 Since the 1970s, PRP
has been the standard of care for patients with PDR. However,
not all eyes with significant capillary nonperfusion develop
new vessels and not all new vessels regress with PRP, indicating
that other factors may be responsible for vessel regression.5,6
Both laboratory and clinical studies have proven that VEGF
is a key angiogenic agent that stimulate retinal neovasculariza-
tion.7,8 Injection of VEGF in vitreous of primates led to retinal
neovascularization, and intravitreal anti-VEGF antibodies caused
regression of these new vessels, demonstrating that intravitreal
anti-VEGF agents cause vessel regression.9,10 Patients with PDR
have high levels of VEGF in the vitreous that reduce with anti-
VEGF injections.8,11
Currently, there are three anti-VEGF agents used in clinical
practice. Bevacizumab and ranibizumab are humanized mono-
clonal antibodies that specifically bind to all isomers of VEGF-A,
with ranibizumab being a Fab antibody fragment compared with
a whole antibody, bevacizumab. A more recently introduced anti-
VEGF agent is aflibercept, which blocks VEGF A, VEGF B,
placental growth factor (PIGF), and Galectin-1.12,13 There are
several clinical studies that have shown that short-term anti-
VEGF therapy cause regression of new vessels in patients with
PDR with reactivation of new vessels once anti-VEGF treatment
is withdrawn.10 The Diabetic Retinopathy Clinical Research
Network (DRCRnet) Protocol S study was the first study to show
that monthly ranibizumab injections for at least 3 months
followed by aggressive retreatment of recurrent or reactivated
retinal neovascularization over 2 years resulted in noninferior
visual outcomes compared with PRP with less need for
vitrectomy and lower prevalence of diabetic macular edema.14
Eyes with PDR with no macular edema required a mean of seven
injections in the first year and a further three injections in the
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second year, suggesting an anti-VEGF–related disease modula-
tion over time. The CLARITY study that compared ‘‘pro re nata’’
intravitreal aflibercept treatment following a loading phase
versus PRP in PDR patients without macular edema showed
superior visual acuity outcomes, a higher proportion of new
vessel regression, and lower incident vitreous hemorrhage and
macular edema with aflibercept by 52 weeks.5 The patients
required a loading phase of three injections followed by a
median of one injection over the next 40 weeks.
These observations with anti-VEGF therapy raise a few
questions. In particular, the exact mechanisms by which these
new vessels regress rapidly with anti-VEGF therapy and the
tendency to recur on withdrawal of anti-VEGF therapy in some
eyes in the short-term remains unclear. Second, repeated anti-
VEGF therapy resulted in fewer recurrencesof neovascularization
and less need for anti-VEGF therapy over time. This raises the
question as to whether capillary nonperfusion stabilizes or
improves with anti-VEGF therapy and whether this stabilization
or improvement in capillary nonperfusion influences the
observed course of new vessel regression. Retinal nonperfusion
due to retinal vascular damage results in hypoxia and the
mechanism of action of PRP is presumably by improving retinal
oxygenation as evidenced by the narrowing of retinal vessel
caliber and new vessel regression. Retinal hypoxia is also a major
stimulus for VEGF, and the role of anti-VEGF on alleviating tissue
hypoxia in proliferative diabetic retinopathy remains unclear.
Studies on vitreous oxygen tension in PDR have shown
significantly lower vitreous oxygen levels in eyes with PDR.15
However, measurement of vitreous oxygen levels to understand
the effect of anti-VEGF therapy in PDR is invasive. Therefore, a
measure of retinal intravascular oxygen saturationsmay indirectly
provide information about the perfusion status of the retina.
Recently, advances in spectral imaging have enabled noninvasive
measurements of retinal intravascular oxygenation and vessel
caliber with excellent reliability.16,17
The aim of this study was to test the hypothesis that repeated
intravitreal aflibercept retards the progression of PDR by 52
weeks by improving retinal oxygen saturation. As direct
measurement of tissue hypoxia is not feasible, we compared the
change in retinal intravascular oxygen saturations, area of retinal
nonperfusion, and area of retinal neovascularization in a
mechanistic substudy of a randomized controlled trial that
compared panretinal photocoagulation versus intravitreal afliber-
cept in proliferative diabetic retinopathy (CLARITY study).
METHODS
Study Design
The CLARITY study is a multicenter, prospective, two-arm,
parallel-group, randomized, noninferiority clinical trial that
compared the outcomes of PRP versus repeated intravitreal
aflibercept for proliferative diabetic retinopathy at 52 weeks.
The study was granted approval by the National Research
Ethics Committee Service London–South East (14/LO/0203).
This mechanistic substudy was performed only at the National
Institute for Health Research Biomedical Research Centre at
Moorfields Eye Hospital, London, United Kingdom. Trial
registration is ISRCTN32207582. The study was conducted
according to the tenets of the Declaration of Helsinki, and
informed consent was obtained from all patients prior to
enrollment into the study.
CLARITY Protocol Synopsis
The CLARITY study consisted of the main study on 232
patients with PDR and a substudy on the mechanistic
evaluation in 40 patients. The main study protocol and primary
outcome have been reported.5 In brief, adults with treatment
na¨ıve or post–laser-treated PDR with no macular edema were
recruited from 22 United Kingdom ophthalmic centers and
randomly assigned (1:1), with stratification including within
center, to repeated intravitreal aflibercept or PRP standard care
for 52 weeks using a web-based computer-generated system.
Only one eye per patient was included in the study. In the PRP
arm, patients were treated with initial PRP at 2-week intervals
until completion of PRP and then reviewed every 8 weeks and
retreated with supplemental PRP based on same retreatment
criteria. In the aflibercept arm, patients were treated with a
loading phase of intravitreal aflibercept injections at 4-week
intervals and then assessed monthly and retreated with
intravitreal aflibercept on a pro re nata basis based on
prespecified retreatment criteria based on retinal vessel
regression patterns for 52 weeks. Retinal color photographs
were taken at all visits, and fundus fluorescein angiography
was performed at baseline and week 52.
Study Population
The mechanistic substudy was done on 40 eyes from 40
patients with proliferative diabetic retinopathy recruited for
the CLARITY study at Moorfields Eye Hospital, London,
between August 22, 2014, and November 30, 2015. These
patients also underwent retinal oximetry and ultra-widefield
color fundus imaging at baseline and 12 and 52 weeks. Ultra-
widefield angiography was performed at baseline and week 52.
Twenty patients were recruited into the aflibercept arm and 20
into the PRP arm.
Retinal Oximetry
Retinal oximetry was performed using the retinal oximeter
(Oxymap T1 device connected to Topcon TRC50-DX fundus
camera; Oxymap ehf., Reykjavik, Iceland). It consists of a
fundus camera with an attached image splitter, as well as a
digital camera. The device captures images at two wave-
lengths, one sensitive to oxyhemoglobin (600 nm) and one
isosbestic (570 nm), where the absorption spectra of
oxyhemoglobin and hemoglobin cross. Computer software
detects retinal vessels and uses relative light intensities inside
and outside a vessel to calculate the optical density (light
absorbance) of a vessel at both wavelengths. The hemoglobin
oxygen saturation (SO2) of a vessel can, therefore, be
calculated because the optical density ratio at these wave-
lengths has been shown to have an approximately inverse
linear relationship with SO2. Optic disc–centered images were
captured through dilated pupils, and the images were 12003
1600 pixels and covered a 508 field of central retina. The
images were captured for both eyes, but only the study eye is
used in this analysis. Images were analyzed using the Oxymap
Analyzer software (Oxymap ehf.). A minimum vessel width of
eight pixels was set, and vessels less than eight pixels were
automatically excluded from the analysis. Oximetry measure-
ments were performed using previously reported methods
whereby the intrasubject reproducibility had an intraclass
correlation coefficient of 0.98.17 In brief, an initial central
circle was used to delineate the optic disc. Two additional
measurement circles are made, one three times the diameter of
the central circle and the following circle 1.5 times the
diameter of the central circle. The area between these two
additional circles centered on the optic disc was analyzed.
Areas where vessel detection would prove inaccurate (branch-
ing, overlapping, intersecting vessels, background hemor-
rhage, or underlying laser scars), and segments of vessels less
than 50 pixels in length were excluded. Vessels to be measured
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were selected manually. Values for each selected vessel were
obtained and subsequently averaged. The retinal oximetry data
streams were extracted from the source data file. Data
collected from the Oxymap software included the mean
arteriolar oxygen saturations (SaO2), mean venular oxygen
saturations (SvO2), mean arterial vessel diameter, and mean
venular diameter.
Ultra-Widefield Color Fundus Photograph
All 40 patients underwent ultra-widefield color fundus
photography using the Optos 200TX (Optos Plc, Dumfermline,
Scotland) ultra-widefield system. The macular-centered 2008
images were used for analysis. Each central color fundus image
was superimposed with the concentric rings template.18 In
brief, this validated method incorporates a macular ring with a
radius of 2.5 disc diameters (DD) and five additional concentric
rings (rings 1–5), each with a 2.5 DD increment in radius. Each
of the six rings (ring M and 1–5) were divided into 12
segments. The area of each cell in each concentric ring was
modified based on the enlargement factor identified using
three-dimensional printed model eyes.19 The enlargement
factor for rings M, 1, 2, 3, 4, and 5 were 1.08, 1.20, 1.34,
1.54, 1.81, and 1.97, respectively. Ultra-widefield fluorescein
angiogram and ultra-widefield red free images were used as a
reference in identifying the new vessels. The areas of new
vessels on ultra-widefield color fundus images were measured
using ImageJ (National Institutes of Health, Bethesda, MD, USA)
in pixels and then converted to disc areas based on the pixel
count for the corresponding disc area for each image. The
areas of new vessels were corrected based on the location
using the enlargement factors for each ring. The presence of
disc new vessels and/or new vessels elsewhere was also
recorded.
Ultra-Widefield Fundus Fluorescein Angiography
Ultra-widefield fundus fluorescein angiography was performed
using the Optos 200TX ultra-widefield system. The fluorescein
angiography images were acquired after intravenous bolus
infusion of 5 mL 20% fluorescein sodium. The images were
acquired at transit phase (up to 45 seconds), arteriovenous
phases (3 to 4 minutes), and late frames at 5 to 7 minutes. A
single investigator (LN) identified the best macula-centered
fluorescein angiography (FA) image in the arteriovenous phase
from the FA series of each eligible eye. Images where clear
delineation between perfused and nonperfused retina could
not be made were excluded from the analysis. A correction
factor was applied for the flattening of the three-dimensional
image to a two-dimensional image using the Optos V2 Vantage
Pro software. Each selected image was superimposed with the
concentric rings template. The previously validated concentric
rings method was used to measure retinal nonperfusion. In
brief, each segment is graded as ungradable, nonperfused, or
perfused if 50% or more of the segment is involved. In addition
to quantifying nonperfusion, the concentric rings method
allows documentation of location of nonperfusion. The area of
each cell in each concentric ring was modified based on the
enlargement factor identified using the three-dimensional
printed model eyes as described previously. Ring 5 was
excluded from our analysis as the number of ungradable cells
has been reported to be high and suitable for steered images
only. Lasered areas were scored based on the area in between
laser scars and the overall assessment of the perfusion in the
assessed segment. Where ungradable, this was scored as
ungradable. Measurements were performed for all baseline
images for both PRP and aflibercept eyes in one session, and
the exit images were analyzed for both PRP and aflibercept at a
separate time period to reduce any potential bias. Assessors
were masked to the treatment arm.
Study Outcomes
The primary outcome of this study was to compare the change
in arterio-venous differences in retinal vessel oxygenation at
week 12 and week 52 compared with baseline for the eyes
treated with panretinal photocoagulation and intravitreal
aflibercept. The secondary outcomes were to compare the
change in area of retinal nonperfusion at week 52 compared
with baseline and the change in area of neovascularization at
week 12 and week 52 with baseline for eyes treated with
panretinal photocoagulation and intravitreal aflibercept.
Statistical Analysis
The oximetry measurements and area of retinal nonperfusion
were described using means, SD or SE, or medians and
interquartile range (IQR).The outcomes were compared
between both aflibercept and PRP treatment arms at both 12
and 52 weeks for oximetry and area of retinal nonperfusion at
52 weeks using analysis of covariance (ANCOVA) adjusting for
the baseline of the outcome under analysis.20 Comparison
between the area of new vessels was performed using a Mann-
Whitney test because the distribution was skewed. Statistical
significance was set at 0.05, although 95% confidence intervals
(CIs) are presented and interpreted because this is a substudy
within a trial.
RESULTS
The mean age of the cohort was 46.7 years (SD, 12.7), and
32.5% were females. The participant flow diagram is presented
in Figure 1. Retinal oximetry measurements revealed fairly
similar arterial and venous saturations in both treatment groups
at week 12 and week 52 (Fig. 2). The mean arterio-venous
oxygen saturation difference (AVD) at baseline was 36.7% (SD,
10.2%) in the PRP group and 33.4% (SD, 8.2%) in the
aflibercept group. At week 12, the AVD was 36.1% and
35.5% for the PRP and aflibercept groups, respectively. At week
52, the AVD increased in the PRP arm to 39.7% and minimally
changed in the aflibercept arm to 32.5%. The effect size of the
difference between the two groups at 52 weeks, adjusted for
baseline, was 4.0% (95% CI, 0.08, 8.8); Mean arterial and
venous diameter decreased in both groups at week 52, again
with no significant difference between groups (Supplementary
Material).
The mean total area of retinal nonperfusion increased in
both PRP and aflibercept groups at 52 weeks predominantly in
the outer zones, with a mean adjusted difference of 12.0 DA
(95% CI, 20.7, 44.7) for total area of nonperfusion between
the two groups. At baseline, the total area of retinal non-
perfusion in the PRP group was 125.1 DA and 131.2 DA in the
aflibercept group. At week 52, this was 156.1 DA and 158.4 DA
in the PRP and aflibercept groups, respectively. Focusing on
posterior pole nonperfusion alone, the mean area of non-
perfusion at baseline was 15.4 DA and 16.9 DA for the PRP and
aflibercept groups, respectively. This was measured as 19.6 DA
and 14.8 DA for the PRP and aflibercept groups at week 52,
respectively. The difference between the change from baseline
between the PRP and aflibercept was less in the aflibercept
group, with an adjusted difference of5.0 DA (95% CI,13.4,
3.5; P ¼ 0.24). This is detailed in Table 1.
The median total area of retinal neovascularization was 0.98
DA (IQR, 0.42, 1.33) in the PRP group and 0.70 DA (IQR, 0.12,
2.6) in the aflibercept group at baseline. At week 12, there was
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a complete regression for the aflibercept group, whereas the
median total area of new vessels for the PRP group was 0.68
DA (P ¼ 0.019). The median total area of neovascularization
was not statistically significant between groups at week 52:
0.24 DA in the PRP group and 0 DA in the aflibercept group (P
¼ 0.45). This is elaborated in Figure 3. All eyes experienced
total regression of new vessels in the aflibercept group at week
12, whereas in the PRP group, 78.9% (15 of 19) showed partial
regression, with no eyes experiencing total regression; 21.1%
(4 of 19) of eyes in the PRP group had no regression at week
12. At the end of the study, 25% (4 of 16) of eyes in the PRP
group had total regression of new vessels, 62.5% (10 of 16) had
partial regression, and 12.5% (2 of 16) had no regression
compared with baseline. As for the aflibercept group, 55.6%
(10 of 18) had total regression and 44.4% (8 of 18) had partial
regression. This is represented in Table 2.
DISCUSSION
The results from this mechanistic substudy tested within the
CLARITY study, a prospective randomized clinical trial
comparing aflibercept and PRP for proliferative diabetic
retinopathy, suggest that, despite significant rapid regression
of retinal neovascularization with aflibercept compared with
PRP, the changes in total area of retinal capillary nonperfusion
and intravascular oxygen saturation at week 52 compared with
baseline between the aflibercept and PRP cohorts are not
significant.
This study corroborated several other reports that has
shown rapid regression of retinal neovascularization or
significant improvement in diabetic retinopathy severity with
anti-VEGF therapy.5,10,14,21–24 The new vessels regressed
completely after the three loading injections of aflibercept
and more than half of eyes (10 of 18) remained completely
regressed at 52 weeks despite an average of 1.4 supplemental
aflibercept injections over the next 40 weeks, suggesting an
immediate but prolonged effect of aflibercept on regression of
new vessels. On the contrary, the new vessel regression was
much slower and incomplete with PRP by 52 weeks. The
reason for rapid regression of new vessels with anti-VEGF
therapy is unclear. We evaluated whether improved tissue
oxygenation with anti-VEGF therapy contribute to new vessel
regression. As measuring tissue oxygen levels is invasive,
FIGURE 1. Participant flow diagram from screening, baseline, week 12,
and week 52 with number of eyes analyzed for retinal oximetry, area of
new vessels, and area of retinal nonperfusion at each time points.
FIGURE 2. Retinal oximetry measurements for retinal arteries and veins for eyes treated with PRP and intravitreal aflibercept at baseline, week 12,
and week 52 for all eyes and the treatment-na¨ıve subgroup.
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measuring global intravascular oxygen saturation around the
optic disc noninvasively by retinal oximetry is the nearest
surrogate marker of tissue hypoxia.25 A larger difference
between the arterio-venous oxygen saturation represents
better retinal tissue perfusion by the intervening capillaries.
In contrast, minimal or small differences between the oxygen
saturation in the arteries and veins indicate shunting of blood
from arteries to vein bypassing the tissue due to capillary
nonperfusion.
In this study, we observed very minimal change in arterio-
venous oxygen saturation after aflibercept therapy at 52 weeks
compared with an increase in the PRP group, resulting in a 4%
(95% CI,0.08, 8.8) difference between groups. The effect size
of this change that relates to a clinically meaningful impact on
retinal tissue hypoxia is unknown. However, the results concur
with the fact that PRP tends to address the hypoxic insult by
ablating the high oxygen consuming photoreceptors in the
outer retina and improving oxygenation of the inner retina
from the choroid.26,27 On the contrary, anti-VEGF therapy did
not result in a demonstrable change in intravascular oxygen
saturation by 52 weeks, suggesting that the disease modulation
induced by anti-VEGF at least in the short term is not caused by
direct and immediate improvement in oxygenation. Diabetic
retinopathy is a slowly progressing disease. Any change in
tissue hypoxia may take time to manifest as a change in
intravascular oxygen saturation. This is substantiated by the
fact that a difference in intravascular oxygen saturation in the
PRP arm was only observed at 52 weeks and not at 12 weeks,
despite the dramatic ablation of the retina. Based on our
results, we believe that we require a larger sample size with a
longer follow-up to better identify any small differences in
intravascular oxygenation between treatment groups. This is
why we have interpreted the 95% CI to distinguish evidence of
absence of effect conclusions from absence of evidence effect
conclusions.28 Currently, we are also not aware of the amount
of change in tissue hypoxia that is required to reflect a change
in intravascular oxygen saturations. Further studies in this area
are required to better understand this relation.
Campachiaro et al. postulated that VEGF driven leucostasis
may in fact cause retinal capillary closure and worsen retinal
ischemia, and anti-VEGF therapy may act by inhibiting this
positive feedback loop.29,30 Our study shows that the effect of
inhibiting this positive feedback loop on tissue oxygenation by
anti-VEGF may indeed be slow. This effect is independent to
the total regression of new vessels, which is an immediate
effect. On the contrary, the effect of PRP may be a direct
mechanical effect of improving retinal oxygenation from the
choroid rather than by inhibiting the VEGF drive per se as
evidenced by the lack of change in vitreous VEGF levels soon
FIGURE 3. Area of neovascularization between eyes treated with intravitreal aflibercept and PRP at baseline, week 12, and week 52 reported in
median and error bars describing the IQR.




























18/18 (100) 0/19 (0) 12/12 (100) 0/11 (0) 6/6 (100) 0/8 (0)
Partial regression 0/18 (0) 15/19 (78.9) 0/12 (0) 7/11 (63.6) 0/6 (0) 8/8 (100)




10/18 (55.6) 4/16 (25) 6/12 (50) 2/9 (22.2) 3/6 (50) 2/7 (28.6)
Partial regression 8/18 (44.4) 10/16 (62.5) 6/12 (50) 5/9 (55.6) 3/6 (50) 5/7 (71.4)
No regression 0/18 (0) 2/16 (12.5) 0/12 (0) 2/9 (22.2) 0/6 (0) 0/7 (0)
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after PRP. The VEGF level is reported to reduce in quiescent
PDR, suggesting the secondary effects of PRP on VEGF. 8,31
We also found no change in total area of retinal non-
perfusion between treatment groups by 52 weeks after
excluding a 45-point or higher difference between arms. There
have been reports of possible reversal or stabilization of retinal
nonperfusion following anti-VEGF and intravitreal steroid
therapy identifying VEGF as a key factor contributing to retinal
nonperfusion.28,31,32 These studies used different methods in
calculating retinal nonperfusion. Campochiaro et al. evaluated
nonperfusion in the posterior pole only and this may in fact be
a more reliable estimate of risk of retinal neovascularization
than utilizing the whole of the retinal gradable area on wide-
field imaging.29 The positive feedback loop is well illustrated in
the analysis of posterior retinal nonperfusion in the RISE and
RIDE study that showed a decrease in the number of patients
with no posterior nonperfusion by 24 months that then
stabilized with ranibizumab therapy by 36 months.30
Multiple reasons may explain why we found no difference
in retinal nonperfusion between treatment groups. First, we
included eyes with active neovascularization following initial
PRP in both arms. The amount of positive feedback loop and
resultant retinal nonperfusion after initial PRP may indeed
behave differently with further treatment compared with
treatment na¨ıve eyes.
Second, due to the various phenotypes of retinal non-
perfusion in diabetes, an ischemic index or a concentric ring
method of calculating global retinal nonperfusion may not
reliably correlate with new vessel formation. This is further
substantiated by the wide CI noted in our study that is wide
enough to support a 20-point effect in the other direction (95%
CI, 20.7, 44.7). This variable progression of retinal non-
perfusion in our cohort may also explain the varied response to
PRP in clinical practice and the need for repeated laser
treatments in some cases. Finally, isolating the change in area of
nonperfusion to rings M and 1 that represents the posterior
pole, we have found that, in the PRP group, there is an increase
in the mean area of nonperfusion, but in the aflibercept group,
this has decreased; the difference was found to be 5.0 DA
(95% CI,13.4, 3.5; P¼ 0.24). Acknowledging the importance
of posterior pole nonperfusion having a larger effect in
neovascularization, this could potentially provide an explana-
tion to the lasting effects of aflibercept in suppressing
neovascularization beyond its pharmacodynamics.30,32 This
was only evident in all eyes and not seen in treatment na¨ıve
eyes, although the numbers for the treatment na¨ıve eyes are
small.
In our cohort of eyes with PRP, the baseline total area of
retinal nonperfusion was 128.2 DA. In previous reports on
ultra-widefield angiography in diabetic retinopathy, the base-
line ischemic index was reported to be 24% to 31.9%, which
roughly converts to 84 to 108 DA.33,34 These studies reported a
cohort of eyes with diabetic retinopathy but not specifically
eyes with proliferative retinopathy. Therefore, our findings of a
higher baseline area of nonperfusion are expected but also
raise the question as to whether there is a point of no: return
beyond which anti-VEGF therapy may not stabilize or reverse
retinal nonperfusion. In our study, both treatment groups
showed a progression of retinal nonperfusion by 52 weeks.
These eyes may indeed behave similar to ischemic central
retinal vein where the progression to neovascular complica-
tions was not absolved with anti-VEGF therapy.35
The strengths of this study include the prospective and
randomized study design with prespecified outcomes to study
these particular factors. The methodology used for measuring
retinal oximetry and retinal nonperfusion has also been
validated and proven to be reliable. Furthermore, the findings
of this study are novel and to our knowledge have not been
reported previously. The limitation of this study is that, as it is
an exploratory study addressing several factors, the sample size
may allow type 2 errors, thereby accepting the null hypothesis,
as the study may be underpowered for certain outcomes, as
seen where 95% CIs include differences that are clinically
significant. Furthermore, the measurement of retinal non-
perfusion in eyes receiving PRP is a challenge, but we ensured
that only images of good quality whereby clear delineation can
be made between perfused and nonperfused retina are
included in the analysis. This measurement error, if any, is
applicable to both arms and should not influence the change
between arms. There was also no significant difference in the
number of ungradable segments in the PRP and aflibercept
cohorts. Blinding of assessors is difficult in na¨ıve eyes treated
with aflibercept as the lack of laser scars will suggest the
treatment arm.
In conclusion, we showed that the change in intravascular
oxygen saturation observed at 52 weeks in the PRP arm
corroborate with our understanding of the mechanism of PRP.
In contrast, the anti-VEGF effect on retinal hypoxia may indeed
be slow and minimal. On the contrary, eyes receiving
intravitreal aflibercept achieve an earlier and more complete
regression of new vessels compared with eyes receiving
conventional PRP by 52 weeks and precede any changes in
total area of capillary nonperfusion. Our study results highlight
that these treatment options may have synergistic effects in the
management of PDR. Further studies with a larger sample size
of PDR with longer follow-up focusing on central retinal
nonperfusion are required to ratify these observations.
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